Thompson Davis & CO. Inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 5.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,758 shares of the company’s stock after selling 205 shares during the quarter. Johnson & Johnson makes up 0.8% of Thompson Davis & CO. Inc.’s holdings, making the stock its 25th largest position. Thompson Davis & CO. Inc.’s holdings in Johnson & Johnson were worth $583,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Moneta Group Investment Advisors LLC raised its stake in Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after buying an additional 54,326,454 shares during the last quarter. Norges Bank acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $4,609,399,000. Morgan Stanley boosted its stake in Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Johnson & Johnson by 15.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after purchasing an additional 3,849,148 shares in the last quarter. Finally, Savant Capital LLC increased its stake in Johnson & Johnson by 8,568.8% during the 4th quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock valued at $29,637,000 after purchasing an additional 3,588,251 shares in the last quarter. Hedge funds and other institutional investors own 67.57% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on JNJ shares. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Tuesday. StockNews.com assumed coverage on Johnson & Johnson in a research note on Thursday, August 17th. They issued a “strong-buy” rating for the company. Citigroup began coverage on Johnson & Johnson in a research report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 target price on the stock. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Finally, Credit Suisse Group upped their price objective on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Eight research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $171.80.
Johnson & Johnson Price Performance
JNJ stock opened at $164.54 on Thursday. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The firm has a market capitalization of $427.63 billion, a PE ratio of 33.31, a price-to-earnings-growth ratio of 2.81 and a beta of 0.54. The business has a 50 day simple moving average of $166.61 and a 200-day simple moving average of $161.45.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The company had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. During the same period in the prior year, the business earned $2.59 EPS. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. Equities research analysts anticipate that Johnson & Johnson will post 10.75 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be issued a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.89%. Johnson & Johnson’s payout ratio is 96.36%.
Insider Transactions at Johnson & Johnson
In other news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at $10,549,440. The disclosure for this sale can be found here. Insiders sold 47,163 shares of company stock worth $7,928,856 in the last 90 days. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Bear Market vs Recession: What Are the Differences?
- Learn Technical Analysis Skills to Master the Stock Market
- 7 Best AI Mutual Funds (and ETFs) to Sweep the AI Craze
- What is the Death Cross and How Can Investors Use it For Successful Trading?
- Auto Parts Stocks Shift Gears: Which is the Right One to Buy?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
